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a b s t r a c t
Mitral valve disease affects more than 4 million people in the United States. The gold
standard of treatment in these patients is surgical repair or replacement of the valve with a
prosthesis. The MitraClip (Abbott Vascular, Menlo Park, CA) is a new technology, which
offers an alternative to open surgical repair or replacement via a minimally invasive route.
We present an evidence-based clinical update that provides an overview of this technology
as it relates to managing patients with signiﬁcant mitral regurgitation. This review article is
particularly useful to noninterventional cardiologists and interventional cardiologists who
will be managing patients with this novel technology in increased volumes over the next
decade but who do not perform this procedure.
# 2015 Cardiological Society of India. Published by Elsevier B.V. All rights reserved.
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Mitral valve disease is the second most common acquired
valvular heart disease in adults. Severe mitral regurgitation
(MR) is the most common manifestation of mitral valve
disease in the developed world. MR affects more than 4 million
Americans, or almost 10% of patients over the age of 75.1 This
epidemic is increasing in frequency as the population ages.2
MR is classiﬁed as either primary (degenerative) or
secondary (functional). Primary MR from degenerative valve
disease is due to a primary disruption of the mitral valve
apparatus from either prolapsed or ﬂail leaﬂets. Secondary MR
on the other hand is due to remodeling of the left ventricle
resulting in malcoaptation of the mitral leaﬂets.
Severe MR when untreated can lead to progressive
dyspnea, left atrial dilation, permanent atrial ﬁbrillation, left* Corresponding author.
E-mail address: mohamadlazkani@gmail.com (M. Lazkani).
http://dx.doi.org/10.1016/j.ihj.2015.08.025
0019-4832/# 2015 Cardiological Society of India. Published by Elsevierventricular (LV) enlargement, and dysfunction leading to
systolic and diastolic congestive heart failure.3 Severe MR
has an annual mortality rate of up to 5% if untreated.4 Medical
management alone may reduce symptoms but does not alter
the natural history of the disease.3 The gold standard of
treatment is surgical repair or replacement.2 There are a
substantial number of patients who are ineligible for mitral
valve surgery because of prohibitive surgical risk, and for those
patients, MitraClip (Abbott Vascular, Menlo Park, CA) is a new
technology, which may offer an alternative treatment option.
2. Traditional treatment options
Mitral valve surgery is used to treat both primary and
secondary MR. Surgery with mitral valve repair or replacement
has been the standard of care in treating patients with primary B.V. All rights reserved.
Fig. 1 – Industrial illustration of the MitraClip (Abbott
Vascular, Menlo Park, CA) device.
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but surgical consideration is given if the patient requires
another open heart procedure, such as coronary artery bypass
grafting, or in some patients with progressive New York Heart
Association (NYHA) class III and IV heart failure on optimal
medical therapy. The decision to repair or replace is dependent
on valve pathology and local surgical expertise. However,
repair is favored over mitral valve replacement in order to
preserve the native valve and sub-valvular apparatus.
Flail or billowing leaﬂets from prolapse are the most
common pathologies amenable to resection or repair. With
adequate operator experience, these techniques can result in
reduced mortality, reduced risk of endocarditis, and can
preclude the need for lifelong anticoagulation.5–9 Examples
of such techniques include quadrangular and triangular
resection, replacement of ruptured chordae with neo-chordae,
placement of an edge-to-edge stitch to anchor the prolapsing
leaﬂet cusp to the opposing stable cusp, and implantation of
an annuloplasty ring. These techniques for primary mitral
valve pathology have been successful. In those in whom repair
is not feasible, mitral valve replacement can be performed
with either a mechanical or bioprosthetic valve. A mechanical
valve lasts longer than a tissue valve but has the disadvantage
of lifelong anticoagulation.
Unlike primary MR, secondary MR remains a surgical
challenge. The ﬁrst approach to this problem has focused on
annuloplasty – either done surgically or percutaneously.
Signiﬁcant efforts have focused on improving results for
surgical mitral annuloplasty because undersized annuloplasty
rings and lack of durability of surgical annular repair have
remained the Achilles heel of this procedure. Newer adjustable
annuloplasty rings, whose shape and size can be adjusted
postimplantation, have been developed by MitraSolutions®
(MN, USA), DynaTek (MO, USA), and ValTech (Yehuda, Israel).
This technological advance in mitral valve repair has spurred
innovation toward the development of percutaneous annulo-
plasty therapies.
Numerous percutaneous annuloplasty techniques are being
tested in clinical trials. The Carillon Mitral Contour System
(Cardiac Dimensions, Inc., WA, USA) is currently under
investigation in Europe. Alternative direct annuloplasty
approaches have since emerged. A direct suture annuloplasty
system has been developed by MitrAlign® (MA, USA). This
device uses a suture-pledget system to cinch the mitral annulus
and reduce the mitral oriﬁce area. Early results for this
technique have been encouraging.10 Furthermore, Accucinch®
(CA, USA) has developed a similar technology but uses multiple
anchors along the entire posterior annulus, which is also under
early development.11 Finally, the CardioBand® system (Valtech
Cardio, Yehuda, Isreal) uses a transseptal approach to deliver a
ﬂexible ring to the annulus via an automated suture technique.
Animal models have demonstrated short-term success, and
human studies are underway.12
A second approach to this problem of secondary MR focuses
on the leaﬂets themselves. The MitraClip (Abbott Vascular,
Menlo Park, CA) is a percutaneous technology that allows for
minimally invasive repair of the mitral valve (Fig. 1). This
technology is the focus of this review.
In addition to surgical and percutaneous intervention, a
third viable option for secondary MR patients is optimalmedical management of heart failure. The MitraClip repair
system is being compared to optimal medical management, in
addition to biventricular pacing in a randomized control trial
that is currently enrolling patients, known as the Clinical
Outcomes Assessment of the MitraClip Percutaneous Therapy
for Extremely High-Surgical-Risk Patients (COAPT) trial for
functional MR patients with NYHA class III and IV heart failure.
The results of this trial will alter the treatment paradigm for
this very sick cohort of patients.13
3. Overview of technology
The MitraClip (Abbott Vascular, Menlo Park, CA) applies the
concept of the Alﬁeri procedure, which is an ‘‘edge-to-edge’’
surgical technique that creates a double oriﬁce mitral valve by
ﬁxing the cusps of the anterior and posterior mitral leaﬂets
together using a double stitch at the point of maximal
regurgitation.14 The MitraClip is the ﬁrst and only device
currently available for percutaneous treatment of MR. The
Food and Drug Administration (FDA) approved its use
commercially in 2013 for cases of degenerative MR in patients
with prohibitive surgical risk for open surgical repair or
replacement.15 The MitraClip is being investigated for func-
tional MR as part of an Investigational Device Exemption (IDE)
Trial, COAPT, which is actively recruiting patients at the time
this review paper is being written.
The MitraClip procedure is performed by the heart-team
comprising of an interventional cardiologist experienced in
managing patients with mitral valve disease, a cardiac surgeon
experienced in mitral valve surgery, a cardiac anesthesiologist,
an echocardiographer, catheterization laboratory technicians,
nurses, and industry proctors who are trained in the
coordinated delivery and care of this complex therapy. A
cardiac surgeon may be the implanting physician or may be
present in the event a complication occurs. The procedure is
performed in the cardiac catheterization laboratory or Hybrid
Fig. 2 – 3D echocardiographic image of the MitraClip (Abbott
Vascular, Menlo Park, CA) placed within the mitral valve.
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sophageal Echocardiogram (TEE) guidance. TEE is used to
guide transseptal access, steering and orientation of the clip
delivery system and clip toward the mitral valve, and grasping
of the leaﬂets to conﬁrm placement of the device on the
anterior and posterior leaﬂets of the mitral valve (Fig. 2).
Assessment of residual MR after clip deployment is complex.
Pulmonary vein ﬂow pattern, color Doppler assessment,
systolic blood pressure, and mean left atrial pressure before
and after clip deployments are all considered in the decision-
making. Placement of a second clip is frequently necessary
and the mitral valve area and mean gradients are evaluated
prior to placement of a second clip. Due to number of steps
involved in the procedure, the implanting physician needs to
have undergone extensive training on deployment of this
device.
Patients are typically recovered in the catheterization lab
recovery room or postanesthetic care unit. They are then
transferred to a telemetry ﬂoor until they are stable enough for
discharge. The median length of stay, after a MitraClip
procedure, is 2.4 days.16 One of the tremendous advantages
of this procedure is how well it is tolerated even in patients
with severe LV dysfunction and elevated left atrial ﬁllingTable 1 – Results from the EVEREST 2 trial.
Patient population
 279 patients with severe MR who were candidates for mitral valve su
Efﬁcacy
 Surgical repair decreased MR more than MitraClip (Abbott Vascular)®
for mitral valve dysfunction versus 2% in the surgical arm.
 Both groups had improvements in MR, left ventricular indices, heart
degree of MR reduction and LV indices were decreased more in the s
 When MitraClip reduced MR to ≤2 plus, the repair was durable at 5 y
Safety
 Major adverse events in 15% of MitraClip cohort versus 48% of surgic
 Most of the adverse events were blood transfusion, but prolonged in
MR, mitral regurgitation; NYHA, New York Heart Association.pressures. The short recovery times and length of hospitaliza-
tion position this device favorably when compared to mitral
valve repair or replacement in the high and extreme surgical
risk group of patients.
After this procedure, these patients are prescribed dual
antiplatelet therapy (DAPT) for a minimum of 6 months. In
addition, they need infective endocarditis prophylaxis prior to
dental or urologic procedures for 6 months. Anticoagulation
with warfarin or Xa inhibitors is resumed if the patient was
treated with these medications for other conditions like atrial
ﬁbrillation or thrombo-embolic venous disease.
4. Indications for use and desired outcomes
FDA approval was ﬁrst sought in 2010, for treating degenera-
tive and functional MR in high-risk surgical and inoperable
patients. This was denied although the indication was
ultimately narrowed to include only high-risk and inoperable
patients with degenerative MR. Since there was an unmet
clinical need in this subgroup of patients, FDA approval was
granted in 2013.
Treatment for symptomatic functional MR with guideline-
directed medical therapy and cardiac resynchronization
therapy improves symptoms and long-term outcomes.17 Most
of the commercial experience till date in functional MR
patients is from Europe, since Conformité Européenne (CE)
mark was granted 5 years prior to FDA approval.
Despite delays in FDA approval, the only pivotal, random-
ized control trial performed with this device was done in the
USA – the EVEREST 2 clinical trial. In this study, the MitraClip
(Abbott Vascular, Menlo Park, CA) was randomized in 2:1
fashion with mitral valve surgery in 279 patients.18 These
included patients with both degenerative and functional MR.
The primary outcome was freedom from death, surgery for
mitral valve dysfunction, or severe MR. Results of the EVEREST
2 trial are summarized below (Table 1).
The majority of additional data have emerged through
various registries. ACCESS-EU is a postmarket registry of
MitraClip patients. A retrospective evaluation of 567 patients
in this registry was performed.19 Several key differences were
found in the real-world application of the MitraClip device
compared to the EVEREST 2 trial. In the ACCESS-EU registry,
the patients tended to be older and had higher surgical risk
than those evaluated in the EVEREST 2 trial. The anatomicrgery.
. In 12-month follow-up, 20% of MitraClip patients required surgery
 failure functional class (NYHA), and quality of life, although
urgical group.
ears.
al cohort.
tubation was also signiﬁcantly higher in the surgical arm.
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criteria of the EVEREST 2 trial in a substantial number of
patients and the majority of patients had functional MR.
Nonetheless, even in this very sick cohort, clinical outcomes
with the MitraClip demonstrated excellent improvements in
MR reduction, NYHA heart failure classiﬁcation, patient
quality of life, and 6-min-walk test results.19 In a subgroup
analysis of the EVEREST 2 trial, MitraClip was equivalent to
surgery in older patients (≥70 years) and those with functional
MR.3 Although the MitraClip does not have an indication for
functional MR in the USA, it is interesting that preliminary
data from registries, such as ACCESS-EU, have already begun
to suggest beneﬁt with this device in this subgroup.
5. Patient selection
Currently patients deemed suitable for the MitraClip (Abbott
Vascular, Menlo Park, CA) procedure must be at prohibitive risk
for open heart surgery, determined by the heart-team.
Prohibitive surgical risk is frequently due to one of the
following reasons:
(1) 30-day Society of Thoracic Surgeons (STS) predicted
operative mortality risk score of ≥8% for mitral valve
replacement or ≥6% for mitral valve repair.
(2) Porcelain aorta or extensively calciﬁed ascending aorta.
(3) Frailty (assessed by in-person cardiac surgeon consultation).
(4) Hostile mediastinum.
(5) Severe liver disease/cirrhosis (MELD Score >12).
(6) Severe pulmonary hypertension (systolic pulmonary artery
pressure >2/3 systemic pressure).
(7) Right ventricular dysfunction with severe tricuspid regur-
gitation, chemotherapy for malignancy, major bleeding
diathesis, immobility, AIDS, severe dementia, internal
mammary artery at high risk of injury.
In addition to assessing for these surgical risk factors, there
are speciﬁc anatomic criteria that must also be met:
– Coaptation length ≥2 mm.
– Coaptation depth <11 mm.
For ﬂail leaﬂets:
– Flail gap ≤10 mm.
– Arm length (coaptation length) ≤15 mm.
MitraClip has the potential to be used in patients outside
this selective cohort. The results of the COAPT trial may alter
the treatment paradigm for this group of patients with
functional MR that are currently excluded from commercial
use.
6. Complications and long-term outcomes
The risks are remarkably low for the MitraClip (Abbott
Vascular, Menlo Park, CA) procedure in comparison to open
repair and are generally well tolerated. No cardiopulmonarybypass is necessary for this procedure. Even in the pivotal
EVEREST 2 clinical trial, major adverse events of death and
major stroke were similar in both arms of the study.3,16
Patients in the surgical arm had a higher need for blood
transfusion and longer mechanical ventilation times than
patients in the MitraClip arm. New onset atrial ﬁbrillation and
acute renal failure incidence were higher in the MitraClip
group.
A systematic review by Vakil et al. demonstrated that MR
reduction was signiﬁcantly improved with the MitraClip
device with an incidence of moderate to severe MR reduced
to 14.7% of patients.20 The long-term beneﬁt is still unknown
for patients with functional MR. Furthermore, MR has been
found to be reduced from severe to mild with MitraClip in the
vast majority of patients. In addition, it is known from
previous studies on surgical repair of MR that there is a higher
mortality rate with residual MR of greater than mild severity.13
Therefore, all efforts are made to obtain this result, even if it
requires implanting multiple clips to achieve this.
Early on in the experience, only one clip was used during a
case reﬂecting lower rates of improvement of symptoms,
NYHA functional class and MR reduction. However, currently
38% of cases receive two clips and 3% receive greater than two
clips.21 There is no data yet on what the outcomes are for
patients receiving single versus multiple clips. Like with any
new technology, but more so with a device as complex, such as
this, there is a steep learning curve, and that with more
experience outcomes, will continue to improve.
Surgical options after placement of a MitraClip are
preserved. Also, the need for subsequent mitral valve repair
happens to be associated with single leaﬂet detachment and
the risk is highest in the ﬁrst 6 months after placement of the
clip. The other measures of efﬁcacy assessed for the MitraClip
in the pivotal trial were LV size, NYHA functional class, and
quality of life. LV dimensions, including end-diastolic and end-
systolic volumes, were signiﬁcantly reduced in both groups at
12 months when compared to baseline. At 12 months, a NYHA
functional class III or IV was noted in 2% of the percutaneous
repair group as compared to 13% in the surgery group; these
numbers continued to decline or were maintained at 4 years.21
The perceived quality of life also improved in both groups, but
was in favor of the MitraClip arm at 30 days as compared to
surgery due to the additional morbidity and invasiveness of
surgical repair.
All patients receiving the clip commercially are entered into
a nationwide STS database so that national outcomes can be
tracked and data collected on the current patterns of use.
7. Obstacles and barriers to widespread
adoption
The major barrier to widespread adoption of this technology is
the careful and limited roll of this technology in the USA. The
MitraClip (Abbott Vascular, Menlo Park, CA) is currently
available in 75 centers in the United States due to technical
requirements that need to be in place at the facilities offering
this technology. One of the major obstacles is the existence of a
functioning ‘‘heart-team,’’ so that appropriate screening and
patient selection occurs. The SCAI/AATS/ACC/STS have
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 3 9 9 – 4 0 4 403endorsed an expert consensus document outlining the
institutional and operator requirements necessary for the
safe conduct of this procedure.22 Also, each center needs a
skilled echocardiographer with 2D and 3D imaging skills for
optimal screening of patients and intraprocedural guidance.
Another barrier to widespread adoption is the lack of
adequate coverage for this therapy by the Centers of Medicare
and Medicaid Services. Based on data from the EVEREST 2 trial,
the MitraClip is a cost-effective technology when compared to
surgical repair. Including hospital admission, follow-up
hospital stays, postsurgical care during the ﬁrst 12 months,
when compared to surgical repair, the MitraClip reduced
health care costs by $2200 per person.23 In terms of quality-
adjusted life years (QALY) in the EVEREST 2 study with high-
risk patients, the quality of life increased and the cost of
maintenance decreased from year 2 to year 10.24
In the primary modiﬁed intention-to-treat EVEREST 2
population, the MitraClip strategy resulted in a small gain in
QALY through 12 months, modestly reducing costs per patient,
making MitraClip economically dominant.23 Threshold analy-
sis shows that MitraClip would be cost effective at a limit of
$54,000 per QALY gained at $26,200.23
8. Conclusion
With all new technologies, it is important that not only the
hospital staff, including catheterization lab nurses and
technicians, registered nurses, anesthesiologists, but also
the primary care providers are fully engaged and understand
the new device. When there is an overall understanding of the
new technology and its role in the armamentarium in heart
failure management by all providers caring for the subset of
patients with heart failure who have signiﬁcant MR, readmis-
sion and clinical outcomes for these patients can be improved.
In terms of MR, the ﬁrst-line therapy for all patients is still
mitral valve surgery. It has been the gold standard, and when
done by qualiﬁed and experienced surgeons, it has great
outcomes. Surgical repair of the mitral valve has been shown
to improve survival and prevent the development of heart
failure.2 However, there are certain populations of patients that
are not candidates for this procedure; for these patients, the
MitraClip (Abbott Vascular, Menlo Park, CA) is an ideal
alternative.
In summary, the MitraClip is a sophisticated new technology
for treating MR. It is a highly complex system, but it has shown
promising results in reducing MR and the burden of heart
failure. The MitraClip has shown that percutaneous interven-
tion is safe with a high procedural success rate and a low
procedural complication rate. Future studies will look at
MitraClip versus medical management in high-risk groups with
functional MR. Currently, it cannot replace surgical repair, but it
is an option for patients that cannot have surgery. Ultimately, it
may be replaced by transcatheter mitral valve replacement but
that technology is at least a decade away from approval.
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